{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:54:33Z","timestamp":1790848473982,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Taiho Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s12325-023-02474-5","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T11:02:47Z","timestamp":1678273367000},"page":"1913-1925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8508-3997","authenticated-orcid":false,"given":"Masakazu","family":"Abe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Aogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"issue":"2","key":"2474_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.6004\/jnccn.2012.0018","volume":"10","author":"JM Salsman","year":"2012","unstructured":"Salsman JM, Grunberg SM, Beaumont JL, et al. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw. 2012;10(2):149\u201357.","journal-title":"J Natl Compr Canc Netw"},{"key":"2474_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278","volume":"26","author":"K Gupta","year":"2021","unstructured":"Gupta K, Walton R, Kataria SP. Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends. Cancer Treat Res Commun. 2021;26: 100278.","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"2474_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-013-2727-3","volume":"142","author":"I Kuchuk","year":"2013","unstructured":"Kuchuk I, Bouganim N, Beusterien K, et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Res Treat. 2013;142(1):101\u20137.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"2474_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00520-004-0710-6","volume":"13","author":"CC Sun","year":"2005","unstructured":"Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005;13(4):219\u201327.","journal-title":"Support Care Cancer"},{"key":"2474_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","volume":"99","author":"S Sommariva","year":"2016","unstructured":"Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit Rev Oncol Hematol. 2016;99:13\u201336.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2474_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00520-019-04778-1","volume":"28","author":"H Woopen","year":"2020","unstructured":"Woopen H, Richter R, Chekerov R, et al. Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213. Support Care Cancer. 2020;28(1):73\u20138.","journal-title":"Support Care Cancer"},{"issue":"1","key":"2474_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T, et al. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol. 2021;26(1):1\u201317.","journal-title":"Int J Clin Oncol"},{"key":"2474_CR8","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis (Version 2.2022). 2022. https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 26 Apr 2022."},{"issue":"1","key":"2474_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00520-016-3313-0","volume":"25","author":"J Herrstedt","year":"2017","unstructured":"Herrstedt J, Roila F, Warr D, et al. 2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support Care Cancer. 2017;25(1):277\u201388.","journal-title":"Support Care Cancer"},{"issue":"24","key":"2474_CR10","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/JCO.20.01296","volume":"38","author":"PJ Hesketh","year":"2020","unstructured":"Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782\u201397.","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"2474_CR11","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27(Suppl 5):v119\u201333.","journal-title":"Ann Oncol"},{"key":"2474_CR12","unstructured":"GlobeNewswire. Taiho Pharmaceutical obtains approval to manufacture and market NK1 receptor antagonist Arokaris\u00ae I.V. infusion 235mg in Japan 2022."},{"key":"2474_CR13","unstructured":"Helsinn Therapeutics US Inc. AKYNZEO\u00ae (netupitant and palonosetron) capsules, for oral use, and AKYNZEO\u00ae (fosnetupitant and palonosetron) for injection, for intravenous use: prescribing information. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/210493Orig1s003lbl.pdf. Accessed 26 Apr 2022."},{"key":"2474_CR14","unstructured":"Helsinn Birex Pharmaceuticals Ltd. Akynzeo 300 mg\/0.5 mg hard capsules and Akynzeo 235 mg\/0.25 mg powder for concentrate for solution for infusion: summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/akynzeo-epar-product-information_en.pdf. Accessed 26 Apr 2022."},{"issue":"2","key":"2474_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.21.01315","volume":"40","author":"A Hata","year":"2022","unstructured":"Hata A, Okamoto I, Inui N, et al. Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE. J Clin Oncol. 2022;40(2):180\u20138.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2474_CR16","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/cncr.34088","volume":"128","author":"K Matsuura","year":"2022","unstructured":"Matsuura K, Tsurutani J, Inoue K, et al. A phase\u00a03 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC. Cancer. 2022;128(8):1692\u20138.","journal-title":"Cancer"},{"issue":"6","key":"2474_CR17","first-page":"760","volume":"30","author":"K Shimada","year":"2003","unstructured":"Shimada K, Taguchi S. Management of nausea, vomiting and anorexia due to anticancer agents [in Japanese]. Gan To Kagaku Ryoho. 2003;30(6):760\u20134.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"Suppl 1","key":"2474_CR18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00520-018-4131-3","volume":"26","author":"M Aapro","year":"2018","unstructured":"Aapro M. CINV: still troubling patients after all these years. Support Care Cancer. 2018;26(Suppl 1):5\u20139.","journal-title":"Support Care Cancer"},{"key":"2474_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/495704","volume":"2015","author":"S Garcia-Recio","year":"2015","unstructured":"Garcia-Recio S, Gasc\u00f3n P. Biological and pharmacological aspects of the NK1-receptor. Biomed Res Int. 2015;2015: 495704.","journal-title":"Biomed Res Int"},{"issue":"11","key":"2474_CR20","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40265-021-01558-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley M. Netupitant\/palonosetron: a review in chemotherapy-induced nausea and vomiting. Drugs. 2021;81(11):1331\u201342.","journal-title":"Drugs"},{"issue":"11","key":"2474_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1080\/14656566.2018.1494726","volume":"19","author":"L Celio","year":"2018","unstructured":"Celio L, Fabbroni C. Pro-netupitant\/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2018;19(11):1267\u201377.","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"2474_CR22","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1021\/js9803813","volume":"88","author":"JP Krise","year":"1999","unstructured":"Krise JP, Narisawa S, Stella VJ. A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs. J Pharm Sci. 1999;88(9):922\u20137.","journal-title":"J Pharm Sci"},{"issue":"22","key":"2474_CR23","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1002\/cncr.32429","volume":"125","author":"S Sugawara","year":"2019","unstructured":"Sugawara S, Inui N, Kanehara M, et al. Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Cancer. 2019;125(22):4076\u201383.","journal-title":"Cancer"},{"issue":"4","key":"2474_CR24","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/jcph.1338","volume":"59","author":"J Gilmore","year":"2019","unstructured":"Gilmore J, Bernareggi A. Complementary pharmacokinetic profiles of netupitant and palonosetron support the rationale for their oral fixed combination for the prevention of chemotherapy-induced nausea and vomiting. J Clin Pharmacol. 2019;59(4):472\u201387.","journal-title":"J Clin Pharmacol"},{"key":"2474_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105041","volume":"139","author":"G Kurteva","year":"2019","unstructured":"Kurteva G, Chilingirova N, Rizzi G, Caccia T, Stella V, Bernareggi A. Pharmacokinetic profile and safety of intravenous NEPA, a fixed combination of fosnetupitant and palonosetron, in cancer patients: prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy. Eur J Pharm Sci. 2019;139: 105041.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"2474_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jcph.198","volume":"54","author":"T Spinelli","year":"2014","unstructured":"Spinelli T, Calcagnile S, Giuliano C, et al. Netupitant PET imaging and ADME studies in humans. J Clin Pharmacol. 2014;54(1):97\u2013108.","journal-title":"J Clin Pharmacol"},{"issue":"Suppl 9","key":"2474_CR27","doi-asserted-by":"publisher","first-page":"ix520","DOI":"10.1016\/S0923-7534(20)34168-5","volume":"23","author":"C Giuliano","year":"2012","unstructured":"Giuliano C, Lovati E, Funk C, Potthast M, Pietra C. In vitro drug-drug interaction studies with the antiemetic drug netupitant and its major metabolites M1 and M2, involving several human cytochrome P450 isoenzymes [ESMO abstract 1618]. Ann Oncol. 2012;23(Suppl 9):ix520.","journal-title":"Ann Oncol"},{"issue":"10","key":"2474_CR28","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1007\/s00520-013-1855-y","volume":"21","author":"C Lanzarotti","year":"2013","unstructured":"Lanzarotti C, Rossi G. Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer. 2013;21(10):2783\u201391.","journal-title":"Support Care Cancer"},{"issue":"3","key":"2474_CR29","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/1078155215586824","volume":"22","author":"JJ Natale","year":"2016","unstructured":"Natale JJ, Spinelli T, Calcagnile S, et al. Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: review of clinical data. J Oncol Pharm Pract. 2016;22(3):485\u201395.","journal-title":"J Oncol Pharm Pract"},{"key":"2474_CR30","doi-asserted-by":"publisher","unstructured":"Kitamura R, Araki H, Ikeda K. Estimation of brain NK1 receptor occupancy after fosnetupitant administration and its contribution to antiemetic efficacy in Japanese patients [abstract 2-C-P-079]. Presented at The 43rd Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics, Yokohama, Japan; November 30\u2013December 3, 2022. https:\/\/doi.org\/10.50993\/jsptsuppl.43.0_2-CP-079.","DOI":"10.50993\/jsptsuppl.43.0_2-CP-079"},{"issue":"1","key":"2474_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40487-022-00188-2","volume":"10","author":"A Hata","year":"2022","unstructured":"Hata A, Shiraishi Y, Inui N, et al. Exploratory analysis comparing fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blind, phase\u00a03 study (CONSOLE). Oncol Ther. 2022;10(1):253\u201362.","journal-title":"Oncol Ther"},{"issue":"1","key":"2474_CR32","first-page":"379","volume":"35","author":"T Fujii","year":"2015","unstructured":"Fujii T, Nishimura N, Urayama KY, et al. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens. Anticancer Res. 2015;35(1):379\u201383.","journal-title":"Anticancer Res"},{"issue":"5","key":"2474_CR33","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s00520-013-2089-8","volume":"22","author":"AD Leal","year":"2014","unstructured":"Leal AD, Kadakia KC, Looker S, et al. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin\/cyclophosphamide therapy. Support Care Cancer. 2014;22(5):1313\u20137.","journal-title":"Support Care Cancer"},{"issue":"6","key":"2474_CR34","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00520-013-2106-y","volume":"22","author":"JD Lundberg","year":"2014","unstructured":"Lundberg JD, Crawford BS, Phillips G, Berger MJ, Wesolowski R. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. Support Care Cancer. 2014;22(6):1461\u20136.","journal-title":"Support Care Cancer"},{"issue":"10","key":"2474_CR35","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1002\/cam4.2979","volume":"9","author":"K Matsumoto","year":"2020","unstructured":"Matsumoto K, Takahashi M, Sato K, et al. A double-blind, randomized, multicenter phase\u00a03 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide. Cancer Med. 2020;9(10):3319\u201327.","journal-title":"Cancer Med"},{"issue":"5","key":"2474_CR36","doi-asserted-by":"publisher","first-page":"390","DOI":"10.7150\/jca.7706","volume":"5","author":"Y Sato","year":"2014","unstructured":"Sato Y, Kondo M, Inagaki A, et al. Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients. J Cancer. 2014;5(5):390\u20137.","journal-title":"J Cancer"},{"issue":"4","key":"2474_CR37","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3892\/mco.2016.769","volume":"4","author":"T Tsuda","year":"2016","unstructured":"Tsuda T, Kyomori C, Mizukami T, et al. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: a retrospective comparison. Mol Clin Oncol. 2016;4(4):603\u20136.","journal-title":"Mol Clin Oncol"},{"issue":"3","key":"2474_CR38","doi-asserted-by":"publisher","first-page":"e589","DOI":"10.1634\/theoncologist.2019-0527","volume":"25","author":"L Schwartzberg","year":"2020","unstructured":"Schwartzberg L, Navari R, Clark-Snow R, et al. Phase IIIb safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy. Oncologist. 2020;25(3):e589\u201397.","journal-title":"Oncologist"},{"issue":"7","key":"2474_CR39","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/annonc\/mdy169","volume":"29","author":"L Schwartzberg","year":"2018","unstructured":"Schwartzberg L, Roeland E, Andric Z, et al. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018;29(7):1535\u201340.","journal-title":"Ann Oncol"},{"issue":"5","key":"2474_CR40","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, et al. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol. 2015;20(5):855\u201365.","journal-title":"Int J Clin Oncol"},{"key":"2474_CR41","unstructured":"Merck Sharp & Dohme Corp. EMEND (fosaprepitant) for injection, for intravenous use: prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022023s019lbl.pdf. Accessed 26 Apr 2022."},{"key":"2474_CR42","unstructured":"Merck Sharp & Dohme Corp. EMEND (aprepitant) capsules: prescribing information. 2003. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021549s017lbl.pdf. Accessed 26 Apr 2022."},{"issue":"9","key":"2474_CR43","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00432-021-03554-1","volume":"147","author":"Y Sun","year":"2021","unstructured":"Sun Y, Zheng Y, Yang X, et al. Incidence of chemotherapy-induced nausea and vomiting among cancer patients receiving moderately to highly emetogenic chemotherapy in cancer centers in Sichuan, China. J Cancer Res Clin Oncol. 2021;147(9):2701\u20138.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Suppl 2","key":"2474_CR44","first-page":"S84","volume":"26","author":"J Zhu","year":"2018","unstructured":"Zhu J, Li Y, Luo Y, Qin Y, Yang L, Wang Y. The CINV caused by multiple-day cisplatin-based highly emetogenic chemotherapy can last a long period of time in patients with NSCLC [MASCC abstract eP022]. Support Care Cancer. 2018;26(Suppl 2):S84.","journal-title":"Support Care Cancer"},{"key":"2474_CR45","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis (Version 1.2022). 2022. https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed 26 Apr 2022."},{"key":"2474_CR46","unstructured":"Taiho Pharmaceutical. Arokaris\u00ae (fosnetupitant) IV infusion: prescribing information [in Japanese]. 2022. https:\/\/www.info.pmda.go.jp\/go\/pdf\/400107_2391406A1029_1_02. Accessed 27 Sep 2022."},{"issue":"3","key":"2474_CR47","first-page":"337","volume":"40","author":"K Nakamura","year":"2013","unstructured":"Nakamura K, Onikubo T, Takagi H, Shinohara A, Shirasawa Y. Evaluation of usability of an anticancer drug after changing it to liquid formulation [in Japanese]. Gan To Kagaku Ryoho. 2013;40(3):337\u201341.","journal-title":"Gan To Kagaku Ryoho"},{"issue":"2","key":"2474_CR48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Oncol. 2020;21(2):242\u20139.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2474_CR49","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134\u201342.","journal-title":"N Engl J Med"},{"key":"2474_CR50","unstructured":"Taiho Pharmaceutical. CTD module 2 for Arokaris\u00ae IV infusion. Chapter 2.7.4. Clinical safety. 2022. https:\/\/www.pmda.go.jp\/drugs\/2022\/P20220325004\/400107000_30400AMX00182_K101_1.pdf. Accessed 27 Sep 2022."},{"key":"2474_CR51","unstructured":"Taiho Pharmaceutical. CTD module 2 for Arokaris\u00ae IV infusion. Chapter 2.7.1. Biopharmaceutical studies and associated analytical methods. 2022. https:\/\/www.pmda.go.jp\/drugs\/2022\/P20220325004\/400107000_30400AMX00182_K100_1.pdf. Accessed 27 Sep 2022."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02474-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02474-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02474-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T19:11:54Z","timestamp":1682449914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02474-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["2474"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02474-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"22 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}